Opthea Exploring Different Approach To Treating Wet AMD

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 055″]

Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward.

Podcast Guest


Megan Baldwin

Dr. Megan Baldwin is CEO/Managing Director of Circadian Technologies (Opthea) and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases. Dr. Baldwin joined Circadian in 2008 and since then has held various positions.

View Full Profile